Evidence map›Paper›PMID 38454275›Full record

ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2024

Efficacy of Agmatine Treatment in Experimental Acute Pancreatitis Rat Model.

Murat Yeniçeri, Alpaslan Tanoğlu, Musa Salmanoğlu, Zafer Çırak, Mustafa Can Şenoymak, Süleyman Baş, Ayşe Sade Gökçen

Open access · greenAbstract read
In one paragraph

Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Murat YeniçeriDepartment of Internal Medicine, University of Health Sciences, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, İstanbul, Turkey.
Alpaslan TanoğluDepartment of Gastroenterology, Bahçeşehir University Faculty of Medicine, Göztepe Medical Park Hospital, İstanbul, Turkey.
Musa SalmanoğluDepartment of Internal Medicine, University of Health Sciences, Sultan Abdulhamid Han Hospital, İstanbul, Turkey.
Zafer ÇırakDepartment of Internal Medicine, Ministry of Health, Honaz State Hospital, Denizli, Turkey.
Mustafa Can ŞenoymakDepartment of Internal Medicine, University of Health Sciences, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, İstanbul, Turkey.
Süleyman BaşDepartment of Internal Medicine, University of Health Sciences, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, İstanbul, Turkey.
Ayşe Sade GökçenDepartment of Pathology, University of Health Sciences, Sultan Abdulhamid Han Hospital, İstanbul, Turkey.
Sağlık Bilimleri Üniversitesi · TRUniversity of Health Science · KHBahçeşehir University · TRDenizli Devlet Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsAcute pancreatitis which is characterized by pancreatic inflammation can sometimes be difficult to treat because of limited therapeutic options. The purpose of the study was to assess the effects of agmatine in the acute pancreatitis experimental rat model. MATERIALS AND

methodsAn acute pancreatitis model was created with the administration of cerulein in 40 female Sprague-Dawley rats. Agmatine was administered as a protective agent at 5 mg/kg (low dose) and 10 mg/kg (high dose). The rats were divided into 5 groups, each with 8 rats: group 1 (acute pancreatitis); group 2 (acute pancreatitis+low-dose agmatine 5 mg/kg); group 3 (acute pancreatitis+high-dose agmatine 10 mg/kg); group 4 (placebo, acute pancreatitis+saline); and group 5 (sham and saline infusion). All rats were sacrificed 24 hours after the last injection, and the levels of superoxide dismutase, interleukin-1 beta, and tumor necrosis factor-alpha were assessed in blood samples collected via cardiac puncture. Histopathological examination was performed by a pathologist, who was blind to the groups, according to the Schoenberg's pancreatitis scoring index.

resultsThe amylase (16.67 and 37.89 U/L), glutathione peroxidase (13.62 and 18.44 ng/mL), tumor necrosis factor-α (39.68 and 64 ng/mL), interleukin-1 (484.73 and 561.83 pg/mL), and transforming growth factor-β (110.52 and 126.34 ng/L) levels were significantly lower and superoxide dismutase (1.29 and 0.98 ng/L) and malondialdehyde (0.99 and 0.96 nmol/mL) levels were significantly higher in group 3 compared to group 1 (P < .05). Moreover glutathione peroxidase, tumor necrosis factor-α, and transforming growth factor-β levels were lower, and malondialdehyde levels were higher in the group 3 compared to group 2 (P < .05). Although the Schoenberg's pancreatitis scoring index was not significantly different between the high- and low-dose treatment groups, rats who received high-dose treatment had significantly lower scores compared to those with acute pancreatitis group.

conclusionThis is the first study that evaluated the efficacy of agmatine in an experimental model of acute pancreatitis. Agmatine, an anti-inflammatory and antioxidant agent, had a protective effect in an experimental rat model of acute pancreatitis.

Indexed as

AgmatinePancreatitisAcute DiseaseAnimalsCeruletideFemaleGlutathione PeroxidaseMalondialdehydePancreasRatsRats, Sprague-DawleySuperoxide DismutaseTransforming Growth FactorsTumor Necrosis Factor-alphaAgmatineCeruletideGlutathione PeroxidaseMalondialdehydeSuperoxide DismutaseTransforming Growth FactorsTumor Necrosis Factor-alpha

Identifiers

PMID38454275
PMCPMC10837605
OpenAlexW4391291650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.